CLK4 Antibody

What are the optimal conditions for CLK4 antibody validation in Western blotting?

When validating CLK4 antibodies for Western blotting, researchers should consider both positive and negative controls to ensure specificity. For positive controls, use cell lines known to express high levels of CLK4, such as HEK293T cells transfected with CLK4 expression vectors. For negative controls, implement CLK4 knockdown models using siRNA or shRNA approaches.

For optimal Western blotting conditions:

• Use 4-15% gradient gels for better resolution of CLK4 (approximately 65 kDa)

• Transfer proteins at 100V for 90 minutes in 10% methanol transfer buffer

• Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature

• Incubate with primary CLK4 antibody (1:1000 dilution) overnight at 4°C

• Detect with HRP-conjugated secondary antibody (1:5000 dilution)

The efficiency of CLK4 knockdown can be confirmed using qRT-PCR with primers such as 5′-CGGAATTCATGCGGCATTCCAAACGAACTC-3′ and 5′-GCACTCTACAACTTTGCCAAAGGC-3′, with PCR conditions of 94°C (30 sec), 65°C (1 min), 72°C (1 min) for at least 32 cycles .

How should researchers distinguish between CLK4 and other CLK family members in immunological assays?

Distinguishing between CLK4 and other family members (CLK1, CLK2, CLK3) requires careful antibody selection and validation procedures due to high sequence homology between these kinases.

Recommended approach:

• Select antibodies raised against unique regions of CLK4 that have minimal homology with other CLK family members

• Perform cross-reactivity tests with recombinant CLK proteins

• Include parallel detection of other CLK family members as controls

• Validate specificity through knockout/knockdown models of each CLK family member

In PCR-based validation, use CLK4-specific primers and optimize PCR conditions (94°C for 30 sec, 65°C for 1 min, 72°C for 1 min, 32+ cycles) that differ from those used for other family members such as CLK3 (94°C for 30 sec, 55°C for 1 min, 72°C for 1 min, 30+ cycles) .

What tissue fixation and antigen retrieval methods work best for CLK4 immunohistochemistry?

Optimal methods for CLK4 detection in tissue sections include:

Fixation protocols:

• 10% neutral buffered formalin for 24 hours at room temperature

• 4% paraformaldehyde for 4-6 hours at 4°C (preferred for maintaining phosphorylation status)

Antigen retrieval methods:

• Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) for 20 minutes

• For phospho-specific CLK4 detection, use EDTA buffer (pH 9.0)

Blocking and antibody conditions:

• Block with 5% normal goat serum in PBS with 0.1% Triton X-100

• Primary antibody dilution: 1:100-1:200 in blocking buffer, overnight at 4°C

• Secondary antibody: 1:500 for 1 hour at room temperature

This protocol is particularly effective for detecting CLK4 in cardiac tissue samples from models of cardiac hypertrophy, where CLK4 protein levels are significantly reduced in failed hearts of mice subjected to transverse aortic constriction or isoproterenol infusion .

How can researchers verify CLK4 antibody specificity for immunoprecipitation experiments?

Verifying CLK4 antibody specificity for immunoprecipitation requires multiple validation steps:

• Pre-clearing validation:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Include IgG control immunoprecipitations in parallel

• Knockout/knockdown controls:

  • Include samples from CLK4 knockdown cell lines (using validated shRNA sequences such as 5′-GCAAACCGUUGAAGGAAUU-3′)

  • Verify knockdown efficiency via Western blot before proceeding with IP

• Reciprocal co-immunoprecipitation:

  • For protein-protein interaction studies, perform reciprocal co-IPs to confirm interactions

  • When studying CLK4-MITF interactions, validate with both anti-CLK4 and anti-MITF antibodies

• Mass spectrometry verification:

  • Submit IP samples for mass spectrometry analysis to confirm CLK4 identity

  • Look for CLK4-specific peptides to confirm antibody specificity

This approach is particularly important when studying CLK4's interactions with substrates like MITF in ESCC cells or NEXN in cardiomyocytes .

How can researchers accurately assess CLK4 kinase activity in cellular contexts using antibody-based techniques?

Assessing CLK4 kinase activity requires specialized approaches beyond simple protein detection:

In-cell kinase activity assay:

• Immunoprecipitate CLK4 from cell lysates using validated antibodies

• Perform in vitro kinase assays using recombinant substrates (MITF or NEXN)

• Detect phosphorylation via phospho-specific antibodies or 32P incorporation

• Include kinase-dead CLK4-K189R mutant as a negative control

Phospho-substrate antibody approach:

• Develop or source phospho-specific antibodies against known CLK4 substrates (e.g., MITF-pY360, NEXN-pS437)

• Monitor substrate phosphorylation as a proxy for CLK4 activity

• Validate specificity with phosphatase treatments and phospho-deficient mutants

• Compare results between wildtype and kinase-dead CLK4 conditions

These methods are particularly relevant when studying how CLK4's kinase activity is affected by post-translational modifications such as methionine oxidation at M307, which has been shown to impair its kinase activity in ESCC .

What approaches should be used to investigate CLK4 in splicing regulation and how can antibodies facilitate this research?

CLK4's role in alternative splicing regulation can be investigated through several antibody-dependent techniques:

RNA-immunoprecipitation (RIP) assay:

• Cross-link RNA-protein complexes in vivo

• Immunoprecipitate CLK4 and associated RNAs

• Reverse cross-links and isolate RNA

• Analyze by RT-PCR or RNA sequencing to identify associated transcripts

Spliceosome component phosphorylation analysis:

• Immunoprecipitate spliceosome components (e.g., SRSF4, SRSF6)

• Probe with phospho-specific antibodies

• Compare phosphorylation patterns with and without CLK4 inhibition

• Validate with phosphatase treatments

Alternative splicing analysis after CLK4 modulation:

• Perform RNA-seq after CLK4 knockdown or inhibition (e.g., using compound 150441, IC50 = 21.4 nM)

• Analyze for changes in exon inclusion/exclusion events

• Validate findings using RT-PCR for specific splicing events

• Correlate with CLK4 protein levels using antibody-based quantification

This is particularly relevant in pancreatic cancer research, where CLK4 has been implicated in aberrant splicing events driving cancer progression through the phosphorylation of key splicing factors .

How can researchers distinguish between CLK4 protein loss and functional inactivation in disease models?

Distinguishing between CLK4 protein loss and functional inactivation requires a multi-faceted approach:

Protein level vs. activity assessment:

• Quantify total CLK4 protein by Western blotting with antibodies against different CLK4 epitopes

• Measure CLK4 kinase activity using substrate phosphorylation assays

• Compare ratios of active vs. total CLK4 across different disease models

• Assess CLK4 post-translational modifications that may affect function without altering protein levels

Genetic rescue experiments:

• Express wildtype CLK4 in cells with endogenous CLK4 downregulation

• Express kinase-dead CLK4-K189R mutant as a control

• Assess restoration of downstream functions (e.g., MITF phosphorylation, substrate autophagic degradation)

• Quantify phenotypic rescue using appropriate functional assays

This approach has been successfully used in cardiac-specific CLK4-knockout mice (Clk4-cKO), where cardiac hypertrophy and dysfunction were observed. Importantly, these phenotypes could be rescued through the restoration of downstream substrate (NEXN) phosphorylation, indicating that the phenotype resulted from loss of CLK4 kinase activity rather than scaffold functions .

What are the best strategies for monitoring CLK4 subcellular localization changes under different cellular stresses?

Monitoring CLK4 subcellular localization under stress conditions requires sophisticated imaging and fractionation approaches:

Immunofluorescence microscopy:

• Fix cells using paraformaldehyde to preserve native protein localization

• Permeabilize with 0.1% Triton X-100

• Block with 5% BSA or normal serum

• Incubate with CLK4 primary antibody (1:200 dilution)

• Co-stain with markers for different cellular compartments (nucleus, cytoplasm, ER, etc.)

• Analyze co-localization using confocal microscopy and quantitative image analysis

Subcellular fractionation and Western blotting:

• Isolate nuclear, cytoplasmic, and other cellular fractions

• Confirm fraction purity using compartment-specific markers

• Perform Western blotting for CLK4 in each fraction

• Quantify relative distribution changes after stress induction

Live-cell imaging (for transfected systems):

• Generate fluorescent protein-tagged CLK4 constructs

• Validate proper localization using antibody staining of endogenous CLK4

• Perform time-lapse imaging during stress induction

• Quantify trafficking between compartments

This approach is particularly valuable when studying redox-sensitive responses of CLK4, as its methionine oxidation at M307 has been shown to impair kinase activity and may also affect localization under oxidative stress conditions in ESCC cells .

How can researchers effectively use CLK4 antibodies to study its role in cardiac hypertrophy models?

Studying CLK4's role in cardiac hypertrophy requires specialized approaches:

Tissue-specific expression analysis:

• Perform immunohistochemistry on cardiac tissue sections from normal and hypertrophic hearts

• Use Western blotting to quantify CLK4 protein levels in whole heart lysates

• Compare CLK4 expression across different cardiac regions (atria, ventricles, septum)

• Correlate CLK4 levels with hypertrophy markers (e.g., BNP, ANP)

In vivo CLK4-substrate interaction studies:

• Perform co-immunoprecipitation of CLK4 and NEXN from cardiac tissue

• Analyze NEXN phosphorylation status using phospho-specific antibodies

• Compare wildtype mice to those with cardiac-specific Clk4 knockout (Clk4-cKO)

• Assess correlation between CLK4-NEXN interaction, NEXN phosphorylation, and cardiac function

Rescue experiments in CLK4-deficient models:

• Deliver AAV vectors expressing CLK4 or phosphomimetic NEXN-S437E to Clk4-cKO mice

• Monitor cardiac function via echocardiography

• Assess cardiomyocyte size reduction via wheat germ agglutinin (WGA) staining

• Quantify fibrosis reduction using Masson's trichrome staining

This approach has demonstrated that CLK4 deficiency leads to pathological cardiac hypertrophy with progressive left ventricular systolic dysfunction and heart dilation, which can be ameliorated by restoring phosphorylation of its substrate NEXN .

What are the common pitfalls in CLK4 antibody-based detection and how can they be addressed?

Researchers frequently encounter several challenges when working with CLK4 antibodies:

Cross-reactivity with other CLK family members:

• Problem: CLK family proteins share significant sequence homology

• Solution: Validate antibody specificity using CLK4 knockout/knockdown samples and recombinant CLK proteins

• Verification: Confirm that antibody does not detect CLK1, CLK2, or CLK3 in overexpression systems

Post-translational modification interference:

• Problem: Modifications like methionine oxidation at M307 may mask epitopes

• Solution: Use multiple antibodies targeting different CLK4 regions

• Verification: Compare detection patterns in oxidizing vs. reducing conditions

Antibody batch variation:

• Problem: Different lots may show variable specificity and sensitivity

• Solution: Validate each new antibody lot against a standard sample

• Verification: Maintain a reference lysate from CLK4-expressing cells for quality control

Low endogenous expression levels:

• Problem: Endogenous CLK4 may be difficult to detect in some tissues

• Solution: Implement signal amplification methods (e.g., enhanced chemiluminescence, tyramide signal amplification)

• Verification: Include positive controls with known CLK4 expression levels

Proper handling of these challenges is critical when studying CLK4's roles in cancer progression and cardiac function, where accurate quantification is essential for understanding disease mechanisms .

How can researchers differentiate between active and inactive forms of CLK4 using antibody-based techniques?

Distinguishing active from inactive CLK4 requires specialized approaches:

Phospho-specific antibodies:

• Target known activating phosphorylation sites on CLK4

• Compare ratios of phosphorylated to total CLK4

• Validate with phosphatase treatments and phospho-deficient mutants

Activity-based protein profiling:

• Use activity-based probes that bind only to active kinases

• Immunoprecipitate CLK4 and detect probe labeling

• Compare labeling across different conditions (e.g., oxidative stress, hypoxia)

Conformation-specific antibodies:

• Develop antibodies that recognize the active conformation of CLK4

• Validate using known CLK4 activators and inhibitors

• Compare detection of wildtype vs. constitutively active CLK4 mutants

Substrate phosphorylation as proxy:

• Monitor phosphorylation of direct CLK4 substrates (MITF at Y360, NEXN at S437)

• Normalize to total substrate and CLK4 levels

• Validate specificity with CLK4 inhibitors (e.g., compound 150441, IC50 = 21.4 nM)

This approach is particularly valuable when studying how methionine oxidation at M307 impairs CLK4 kinase activity in conditions like esophageal carcinoma, where post-translational modifications affect function without necessarily altering protein levels .

What are the emerging areas of CLK4 research where antibody-based techniques will be critical?

CLK4 research is rapidly expanding, with several promising areas where antibody-based techniques will be essential:

Cancer therapy response monitoring:

• Using CLK4 antibodies to track kinase activity during treatment with CLK4 inhibitors

• Monitoring changes in alternative splicing patterns as biomarkers of response

• Assessing CLK4-dependent pathways in therapy-resistant tumors

Cardiac disease progression:

• Quantifying CLK4 expression changes during heart failure development

• Monitoring CLK4-NEXN interactions as potential disease biomarkers

• Assessing therapeutic interventions targeting the CLK4-NEXN axis

Redox biology and metabolism:

• Studying how oxidative stress affects CLK4 activity in metabolic disorders

• Developing redox-sensitive CLK4 detection methods

• Investigating CLK4's role in modulating NADPH/NADP+ ratio and purine synthesis

Novel therapeutic target validation:

• Using antibodies to validate CLK4 inhibitor engagement in tissues

• Developing companion diagnostics for CLK4-targeting drugs

• Monitoring on-target vs. off-target effects of splicing modulators

These emerging research areas build on recent findings about CLK4's roles in esophageal carcinoma progression, cardiac hypertrophy, and pancreatic cancer, where it functions as a critical regulator of alternative splicing, metabolism, and cellular homeostasis .